Breakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression

HYD LLC Hungary

is preparing for the next stage: translating in vitro and in vivo models into clinical studies. Their 30 years of foundational research now provide a robust platform for launching a new generation of anticancer treatments based on isotopic modulation. HYD LLC is actively seeking investment partners and pharmaceutical collaborators to conduct Phase II/III clinical trials and complete drug registration.

HYD LLC has announced that registration is now open for the 5th International Congress on Deuterium Depletion (ICDD2026) in Budapest, Hungary, between 22 and 23 April 2026.
 
Registration, abstract submission, and accommodation booking at the Congress venue can be completed via the online https://lnkd.in/dHXm5EQa

Company Information:

HYD LLC for Cancer Research and Drug Development has been leading research into deuterium depletion and its application in drug development since 1993. Lead researcher Dr. Gábor Somlyai was the first to recognize the biological and physiological importance of naturally occurring deuterium. His research confirmed the anticancer effects of deuterium depletion. The strategic replacement of deuterium in water and organic molecules with hydrogen offers new opportunities to prevent and treat cancer and metabolic diseases.
HYD LLC has established a DDW production facility and received a manufacturing license with GMP (Good Manufacturing Practice) certification.

More Information:

HYD LLC for Cancer Research and Drug Development
Web: www.hyd.hu; www.vetera.hu; www.deuteriumdepletion.com
Dr. Gábor Somlyai, Managing Director and Lead Researcher
Phone: [phone]
Email: [e-mail] 

Media Contact:
Name: Gábor Somlyai PhD
Mobil: [phone]

Email: [e-mail]

Website: https://hyd.hu

Contact:
Gábor Somlyai
Founder | HYD LLC
???? [[e-mail] ] | ???? https://hyd.hu

Photo - https://mma.prnewswire.com/media/2903996/HYD_LLC.jpg

View original content:https://www.prnewswire.co.uk/news-releases/breakthrough-study-confirms-hyd-llcs-30-year-research-on-deuterium-modulation-in-cancer-gene-expression-302688115.html